Sébastien Benizri
Post doc

 

Surname / Name: Sébastien Benizri, Ph. D.

Emails: sebastien@benizri.fr ; benizri@cerege.fr

C.V Sébastien Benizri

 

Thesis directors: Pr. Philippe Barthélémy

 

 

Research thesis

Antisense oligonucleotides are known to inhibit mRNA translation into proteins. However, the intracellular delivery and silencing activity of these oligonucleotides remains a challenge. In order to address this delivery issue we are currently developing different strategies allowing the synthesis of Lipid-OligoNucleotide conjugates (LONs). Interestingly, these conjugates self assemble to form nano-shape objects, which can be uptaken by the cells. Moreover, thanks to the LON amphiphile properties drugs and/or hydrophobic contrast agents can be loaded inside the hydrophobic reservoir of the nano-objects. The resulting nanocarriers would be of interest for drug delivery applications. This technology was use for Prostate Cancer (PC), which is one of the most common cancers in industrialized countries. Translationally controlled tumor protein (TCTP) is now recognized as a potential therapeutic target in PC. TCTP is overexpressed in castration-resistant prostate cancer (CRPC), and it has been implicated resistance to treatment. We developed TCTP antisense oligonucleotides to inhibit TCTP expression. Lipid conjugation has dramatically improved the penetration and efficiency of the antisense in inhibiting TCTP expression in the absence of additional transfection agents, both in vitro and in vivo.

 

 

Education

2015 – 2018 – PhD student in interface between chemistry and biology, University of Bordeaux, France

2014 – Master degree in BioChemistry, University of Bordeaux, France

2011 – BTS in Bioanalysis and control, Raoul Dautry high school, Limoges, France

 

 

Internship and work experiences

Since 2019-12 – “Environnement Durable” Team – Cerege – Arbois Pasteur, Aix-en-Provence, France

Post-Doc

“Interactions, reactivity and stability of nucleic acids and “associated” nucleotides with alumino-silicated nano-structures”

 

2018 – 2019 – ChemBioPharm ARNA – INSERM U1212, Bordeaux, France

Post-Doc

“Synthesis and characterization of amphiphilic oligonucleotides for antibacterial applications and biodistribution in mouse model”

 

2015 – 2018 – ChemBioPharm ARNA – INSERM U1212, Bordeaux, France

PhD student – Supervisor : Pr. Philippe Barthélémy

“Synthesis and characterization of amphiphilic oligonucleotides for therapeutic application”

 

2014 ChemBioMed ARNA – INSERM U869, Bordeaux, France

2 months Supervisor: Pr. Philippe Barthélémy

“Formulation of functionalized liposomes, nucleic acid vector by encapsulation”

 

2014 Training period within ChemBioMed ARNA – INSERM U869, Bordeaux, France

6 months Supervisor: Pr. Philippe Barthélémy

“Vectorization of antisense oligonucleotides and interfering RNAs to potentiate breast cancer cells of luminal subtype B with tamoxifen”

 

2013 Training period within Extracellular Vesicles and Membrane Repair, Pessac, France

3 months Supervisor: Pr. Alain Brisson

“Quantification of extracellular microvesicles of blood plasma by flow cytometry”

 

2010 Training period within “Unité de Génétique Moléculaire Animal” (UGMA), Limoges, 14 weeks France

Supervisor: Lionel Forestier

“Molecular analysis of ENU murine mutants using refinement by homozygosity mapping with SNP and candidate gene approach ”

 

 

Publications

  1. Kauss, T.; Arpin, C.; Bientz, L.; Nguyen, PV.; Vialet, B.; Benizri, S.; Barthélémy,P. Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance. Sci. Rep. 2020. https://doi.org/10.1038/s41598-020-58047-x
  2. Benizri, S.; Gissot, A.; Martin, A.; Vialet, B.; Grinstaff, M. W.; Barthélémy, P. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications. Bioconjug. Chem., 2019. https://doi.org/10.1021/acs.bioconjchem.8b00761.
  3. Benizri, S.; Ferey, L.; Alies, B.; Mebarek, N.; Vacher, G.; Appavoo, A.; Staedel, C.; Gaudin, K.; Barthélémy, P. Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery. Nanoscale Res. Lett., 2018, 13, 17. https://doi.org/10.1186/s11671-017-2420-2.
  4. Karaki, S.; Benizri, S.; Mejías, R.; Baylot, V.; Branger, N.; Nguyen, T.; Vialet, B.; Oumzil, K.; Barthélémy, P.; Rocchi, P. Lipid-Oligonucleotide Conjugates Improve Cellular Uptake and Efficiency of TCTP-Antisense in Castration-Resistant Prostate Cancer. J. Controlled Release, 2017, 258, 1–9. https://doi.org/10.1016/j.jconrel.2017.04.042.
  5. Ramin, M. A.; Baillet, J.; Benizri, S.; Latxague, L.; Barthélémy, P. Uracile Based Glycosyl-Nucleoside-Lipids as Low Molecular Weight Organogelators. New J. Chem., 2016, 40 (12), 9903–9906. https://doi.org/10.1039/C6NJ02675C.
  6. Oumzil, K.; Benizri, S.; Tonelli, G.; Staedel, C.; Appavoo, A.; Chaffanet, M.; Navailles, L.; Barthélémy, P. pH-Cleavable Nucleoside Lipids: A New Paradigm for Controlling the Stability of Lipid-Based Delivery Systems. ChemMedChem, 2015, 10 (11), 1797–1801. https://doi.org/10.1002/cmdc.201500381.

 

 

 

Patents

  1. Rocchi, P.; Barthelemy, P.; Benizri, S.; Cherif, C.; El Kaoutari, A. Antisense Oligonucleotides Effective to Reduce the Expression of Menin in Cancer Cells of a Subject. WO/2017/134252, August 11, 2017.
  2. Rocchi P.; Barthélémy P.; Benizri S.; Branger N.; Camplo M.; Siri O.; Karaki S. Encapsulation of Phenazine and Derivatives Thereof. Ongoing

 

Category
Previous Members